This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Sodium clodronate oral


Oral formulations of sodium clodronate.

Drugs List

  • CLASTEON 400mg capsules
  • CLASTEON 800mg tablets
  • LORON 520mg tablets
  • sodium clodronate 400mg capsules
  • sodium clodronate 520mg tablets
  • sodium clodronate 800mg tablets
  • Therapeutic Indications


    Hypercalcaemia due to malignant disease
    Management of osteolytic bone lesions
    Pain in bone due to neoplastic disease

    Management of osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with breast cancer or multiple myeloma.

    Maintenance of clinically acceptable calcium levels in patients with hypercalcaemia due to malignant disease who have already been treated with intravenous sodium clodronate.



    Capsules 400mg/ Tablets 800mg
    1600mg daily as a single dose in the morning. If required the dose may be increased, and the portion exceeding 1600mg should be taken separately later in the day.
    Maximum daily dose: 3200mg.

    Tablets 520mg
    1040mg daily as a single dose or twice a day regimen. If required the dose may be increased.
    Maximum daily dose: 2080mg.

    Patients with Renal Impairment

    Daily doses exceeding 1600mg should not be used continuously in patients with renal impairment.

    Patients with creatinine clearance between 50 and 80ml/minute: No dose reduction is recommended.
    Patients with creatinine clearance between 30 and 50ml/minute: The daily dose should be reduced by a quarter of the recommended adult dose. (Only applies to 400mg and 800mg sodium clodronate oral dosage formulations.)
    Patients with creatinine clearance between 10 and 30ml/minute: The daily dose should be reduced to half the recommended adult dose.
    Patients with creatinine clearance below 10ml/minute: contraindicated.


    A single daily dose should be taken in the morning on an empty stomach with a glass of water. The patient should be advised not to eat, drink (other than water) or take other oral medication for 1 hour after taking the tablets.

    If the daily dose is to be divided the first dose should be taken in the morning on an empty stomach with a glass of water. The second dose should be taken between meals, this should be more than 2 hours after and 1 hour before eating, drinking (other than water) or taking other oral medication.


    Children under 18 years
    Acute severe inflammatory gastrointestinal disorder
    Renal impairment - creatinine clearance below 10ml/minute

    Precautions and Warnings

    Restricted sodium intake
    Glucose-galactose malabsorption syndrome
    Lactose intolerance
    Renal impairment - creatinine clearance 10-50ml/minute

    Reduce dose in patients with glomerular filtration rate 10-50ml/min
    Some formulations contain more than 1mmol (23mg) sodium per dose
    Consider a dental exam & appropriate preventive dentistry before treatment
    Some formulations contain lactose
    Consider dose adjustment if changing formulation;bioavailability may differ
    Ensure patient has adequate fluid intake
    Evaluate renal function before and during treatment
    Monitor serum calcium and phosphate levels before and during treatment
    Advise patient to report any ear pain, discharge or infection
    Advise patient to report any new thigh, hip or groin pain
    Consider osteonecrosis of external auditory canal if ear symptoms occur
    Patients should seek medical attention upon signs of oesophageal irritation
    Consider discontinuation if atypical femur fracture is suspected
    Consider withholding treatment if osteonecrosis of the jaw occurs
    Avoid giving oral dose at same time as food, antacids or mineral supplement
    Advise patient of need for high oral hygiene standards
    Patient to inform dentist of bisphosphonate use: avoid invasive procedures

    Atypical femoral fractures have been reported in patients primarily receiving long term treatment with bisphosphonates. Fractures often occur with little trauma and some patients might experience thigh or groin pain. As fractures are often bilateral, the contralateral femur should be examined upon femoral shaft fracture. Consider discontinuation of bisphosphonate treatment in patients suspected of having an atypical femur fracture.

    Invasive dental procedures should be avoided in patients taking bisphosphonates. Advise patients to inform their dentist that they are taking bisphosphonates and should not undergo invasive dental procedures. There is no data available to suggest discontinuation of bisphosphonate treatment prior to dentistry reduces the risk of osteonecrosis of the jaw. Recovery from such procedures is likely to be prolonged.

    Pregnancy and Lactation


    Sodium clodronate is contraindicated during pregnancy.

    The manufacturer does not recommend using sodium clodronate during pregnancy. Animal studies have shown reproductive toxicity. Human data is limited and as such a potential risk cannot be ruled out.


    Sodium clodronate is contraindicated during breastfeeding.

    The manufacturer advises that the patient either discontinues sodium clodronate or discontinues breastfeeding. The presence of sodium clodronate in human breast milk is unknown. A risk to neonates cannot be excluded.

    Side Effects

    Acute renal failure
    Atypical femoral fracture
    Bone pain
    Decrease in serum phosphate
    Exfoliative dermatitis
    Hypersensitivity reactions
    Increase in alkaline phosphatase
    Increase in lactate dehydrogenase
    Increase in serum transaminases
    Joint pain
    Leucopenia (transient)
    Muscle pain
    Osteonecrosis (primarily of the jaw)
    Osteonecrosis of the external auditory canal
    Renal impairment
    Respiratory symptoms
    Serum creatinine increased


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: October 2019

    Reference Sources

    Summary of Product Characteristics: Clasteon 400mg Capsules. Kent Pharmaceuticals. Revised February 2017.
    Summary of Product Characteristics: Clasteon 800mg Tablets. Kent Pharmaceuticals. Revised February 2017.
    Summary of Product Characteristics: Loron 520 Film-coated Tablets. Roche Products Ltd. Revised August 2018.

    NICE Evidence Services Available at: Last accessed: 28 October 2019

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.